| Literature DB >> 24719523 |
Ana Flávia Teixeira Rossi1, Márcia Cristina Duarte1, Ayla Blanco Poltronieri1, Marina Curado Valsechi1, Yvana Cristina Jorge1, Dalísio de-Santi Neto2, Paula Rahal1, Sonia Maria Oliani1, Ana Elizabete Silva1.
Abstract
OBJECTIVE: Annexin-A1 (ANXA1/AnxA1) and galectin-1 (LGALS1/Gal-1) are mediators that play an important role in the inflammatory response and are also associated with carcinogenesis. We investigated mRNA and protein expression in precancerous gastric lesions that participate in the progression cascade to gastric cancer, such as intestinal metaplasia (IM) and gastric ulcer (GU).Entities:
Mesh:
Substances:
Year: 2014 PMID: 24719523 PMCID: PMC3955591 DOI: 10.1155/2014/478138
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Sequence of primers and size of the fragments generated to determine H. pylori infection and cagA genotype.
| Gene | Position | GenBank* access | Sequence | Fragment size (bp) |
|---|---|---|---|---|
|
| 45844322 | NW_004078084.1 | F: TTTGGAAGTGCTCACAGCAG | 226 |
|
| 754333 | CP006610.1 | F: TTCCTGATGGGACCAAACTC | 316 |
|
| 37 | AY762757.1 | F: CCTGCCGTTTTAGGAAACAA | 413 |
|
| 1 | JF798698.1 | F: TGACTAACGAAACTATTGATC | 244 |
*http://www.ncbi.nlm.nih.gov/genbank/.
Figure 1Distribution of relative gene expression (Log2RQ) of ANXA1 and LGALS1 (a and b) and mean values of relative gene expression in intestinal metaplasia and gastric ulcer groups (c).
Relative gene expression of ANXA1 and LGALS1 mRNA in the intestinal metaplasia (IM) and gastric ulcer (GU) groups and comparison according to risk factors.
| Variables |
|
| ||||||
|---|---|---|---|---|---|---|---|---|
| IM | GU | IM | GU | |||||
| ( | ( | ( | ( | |||||
| mRNA | ||||||||
| Mean ± SD | 6.22 ± 1.43 | 6.69 ± 1.56 | 0.35 ± 1.37 | 0.69 ± 1.65 | ||||
| (range) | (2.55–8.90) | (2.42–8.80) | (−3.54–2.86) | (−4.04–3.13) | ||||
|
| 0.21 | 0.38 | ||||||
| Age (years) | ||||||||
| <60 | 16 (44.5%) | <55 | 15 (51.7%) | <60 | 16 (44.5%) | <55 | 15 (51.7%) | |
| (Mean ± SD) | 6.48 ± 1.55 | 6.81 ± 1.71 | 0.62 ± 1.11 | 0.63 ± 1.84 | ||||
| ≥60 | 20 (55.5%) | ≥55 | 14 (48.3%) | ≥60 | 20 (55.5%) | ≥55 | 14 (48.3%) | |
| (Mean ± SD) | 6.00 ± 1.32 | 6.55 ± 1.43 | 0.14 ± 1.53 | 0.76 ± 1.50 | ||||
|
| 0.34 | 0.66 | 0.28 | 0.83 | ||||
| Gender | ||||||||
| Female | 19 (52.8%) | 8 (27.6%) | 19 (52.8%) | 8 (27.6%) | ||||
| (Mean ± SD) | 6.30 ± 1.34 | 7.07 ± 1.18 | 0.80 ± 1.30 | 1.41 ± 1.26 | ||||
| Male | 17 (47.2%) | 21 (72.4%) | 17 (47.2%) | 21 (72.4%) | ||||
| (Mean ± SD) | 6.12 ± 1.55 | 6.54 ± 1.69 | −0.15 ± 1.29 | 0.42 ± 1.73 | ||||
|
| 0.71 | 0.35 | 0.03* | 0.11 | ||||
| Drinking | ||||||||
| Yes | 10 (27.8%) | 11 (39.3%) | 10 (27.8%) | 11 (39.3%) | ||||
| (Mean ± SD) | 6.12 ± 1.26 | 6.17 ± 1.97 | −0.13 ± 1.75 | 0.29 ± 1.81 | ||||
| No | 26 (72.2%) | 17 (60.7%) | 26 (72.2%) | 17 (60.7%) | ||||
| (Mean ± SD) | 6.26 ± 1.51 | 7.10 ± 1.17 | 0.54 ± 1.17 | 0.88 ± 1.58 | ||||
|
| 0.78 | 0.18 | 0.29 | 0.39 | ||||
| Smoking | ||||||||
| Yes | 26 (72.2%) | 18 (64.3%) | 26 (72.2%) | 18 (64.3%) | ||||
| (Mean ± SD) | 6.26 ± 1.49 | 6.66 ± 1.64 | 0.29 ± 1.49 | 0.46 ± 1.88 | ||||
| No | 10 (27.8%) | 10 (35.7%) | 10 (27.8%) | 10 (35.7%) | ||||
| (Mean ± SD) | 6.11 ± 1.32 | 6.86 ± 1.52 | 0.53 ± 1.01 | 0.98 ± 1.21 | ||||
|
| 0.76 | 0.75 | 0.58 | 0.39 | ||||
|
| ||||||||
| Positive | 14 (38.9%) | 15 (55.5%) | 14 (38.9%) | 15 (55.5%) | ||||
| (Mean ± SD) | 6.70 ± 1.75 | 6.88 ± 1.35 | 0.29 ± 1.61 | 0.94 ± 1.59 | ||||
| Negative | 22 (61.1%) | 12 (44.5%) | 22 (61.1%) | 12 (44.5%) | ||||
| (Mean ± SD) | 5.91 ± 1.11 | 6.47 ± 1.86 | 0.39 ± 1.23 | 0.67 ± 1.77 | ||||
|
| 0.15 | 0.53 | 0.85 | 0.69 | ||||
| Genotype | ||||||||
| Positive | 12 (85.7%) | 10 (66.7%) | 12 (85.7%) | 10 (66.7%) | ||||
| (Mean ± SD) | 6.88 ± 1.81 | 6.82 ± 1.60 | 0.45 ± 1.58 | 0.50 ± 1.68 | ||||
| Negative | 2 (14.3%) | 5 (33.3%) | 2 (14.3%) | 5 (33.3%) | ||||
| (Mean ± SD) | 5.58 ± 0.96 | 6.99 ± 0.81 | −0.62 ± 2.12 | 1.81 ± 1.03 | ||||
|
| 0.20 | 0.77 | 0.55 | 0.16 | ||||
aNonparametric Mann-Whitney test; *significant difference.
Figure 2Expression of annexin-A1 protein in gastric mucosa (a–c). (a) Expression of AnxA1 in normal mucosa (C), predominantly in the cytoplasm of epithelial cells (curved arrow) and stroma (arrowhead). (b) Increased expression after intestinal metaplasia (IM) in the nucleus (arrow), cytoplasm (curved arrow), and stromal region (arrowhead). (c) Higher AnxA1 expression can be observed in peripheral area of gastric ulcer (GU) especially in stroma (arrowhead) and epithelial cells (curved arrow and arrow). (d) Absence of immunoreactivity in the reaction control. Asterisk: goblet cell. Hematoxylin of Harris counterstain. Bar: 20 μm. (e) Densitometry analyses (mean ± SE). *P in relation to C (*P < 0.05; **P < 0.01; ***P < 0.001); + P < 0.05 in relation to IM. a.u.: arbitrary unit.
Figure 3Expression of galectin-1 protein in the gastric mucosa (a–c). (a) Expression of Gal-1 in normal mucosa (C) in the stroma (arrowhead). (b) Intense immunostaining was observed in intestinal metaplasia (IM) in the nucleus (arrow), cytoplasm (curved arrow), and stromal region (arrowhead). (c) Peripheral area of gastric ulcer (GU) with high expression in stroma (arrowhead) and epithelial cells (curved arrow and arrow). (d) Absence of immunoreactivity in the reaction control. Asterisk: goblet cell. Hematoxylin of Harris counterstain. Bar: 20 μm. (e) Densitometry analyses (mean ± SE). *P in relation to C (***P < 0.001). a.u.: arbitrary unit.